Table 3.

Primary outcome: provers identified in the placebo run-in and treatment phase

Study phase medication	N assessed proven	Difference (95% CI)	n (%)
Run-in phase*
Belladonna	101	8 (− 6.3, 9.0)	1.2 (7.9%)
Placebo	105	7	(6.7%)
Treatment phase
Belladonna	101	14 (− 9.3, 10.1)	− 0.4 (13.9%)
Placebo	105	15	(14.3%)

^*All subjects received placebo during the placebo run-in period.